We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to register your medical devices with the Medicines and Healthcare products Regulatory Agency (MHRA) for the markets in Great Britain and Northern Ireland
This guidance provides information on comparator products used in studies supporting abridged marketing authorisation applications
The review of the safety of isotretinoin has concluded.
Covering thalidomide, lenalidomide, and pomalidomide: temporary guidance for pregnancy prevention arrangements for patients taking them during COVID-19
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
The Brucella Reference Unit (BRU) provides laboratory diagnostic and clinical management services for Brucella species.
Emerging techniques on how to prevent or minimise the environmental impacts of hydrogen production by electrolysis of water.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
View highlights of some of our most recently published research on this page. You can also download a complete list of our published research.
Marburg virus is a Filovirus which, along with Ebola virus, can cause a severe and often fatal viral haemorrhagic fever (VHF).
The Subsidy Advice Unit (SAU) has accepted a request for a report providing advice to DESNZ and DBT concerning the proposed EII Exemption from Nuclear RAB Policy Costs subsidy scheme.
The Subsidy Advice Unit (SAU) has accepted a request for a report providing advice to DESNZ and UKIB concerning the proposed Sizewell C FID scheme.
A rapid evidence assessment and qualitative study that aims to improve understanding of the practice, experience and effect of conversion therapy.
You can claim relief to pay no Customs Duty and VAT if you're importing therapeutic substances of human origin, blood-grouping or tissue-typing reagents, or related packaging, solvents and accessories.
Consultation on banning conversion therapy, and research reports on the nature, quality and quantity of evidence on its prevalence and practice.
How test manufacturers or distributors can apply for approval of their tests to sell on the UK market.
The equality assessment presents the impacts of the introduction of the hormone replacement therapy prescription prepayment certificate (HRT PPC).
Treatment forms (T1 to T6) for use in connection with patients detained under the Mental Health Act 1983, who are in receipt of treatment for a mental disorder.
The National Treatment Agency for Substance Misuse (NTA) was established in 2001 to improve the availability, capacity and effectiveness of drug treatment. It became part of Public Health England in 2013.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.